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Objective: Compare long-term results of endovascular treatment and standard open repair of abdominal aortic aneurysms
in a multicenter, concurrent-controlled trial.
Methods: 334 subjects were treated with standard open repair (control, n  99) or the original EXCLUDER Bifurcated
Endoprosthesis (test, n  235). Five-year clinical evaluations and corelab radiographic results are analyzed.
Results: Overall and aneurysm-related survival are similar. There have been ten open conversions, most frequently for
enlarging sacs without endoleak. Two patients died after conversion. Including reinterventions and complications of
reinterventions as adverse events, there is significant, persistent long-term reduction in major adverse events. At 5 years,
corelab reported 0% limb narrowing, 0% trunk migration, 0% component (contralateral leg, aortic extender, and iliac
extender) migration, 0% fracture, endoleak in 3% (2 type II/68), and aneurysm growth (>5 mm compared to baseline)
in 38% (30/78) of the test group. There are no aneurysm ruptures in either test or control group.
Conclusions: After 5 years follow-up, endovascular repair is a safer and effective treatment compared with open surgical
repair for abdominal aortic aneurysms. Major adverse events are less frequent with the endograft despite the need for late
reinterventions. Aneurysm expansion is observed in nearly two-fifths of patients but is not associated with endoleak or
aneurysm rupture. Multicenter clinical trials are evaluating a newer version of this device designed to avoid this high rate
of sac expansion. (J Vasc Surg 2007;45:885-90.)Since the report of endovascular abdominal aortic an-
eurysm repair (EVAR) appeared in 1991 by Parodi et al,1
several endoluminal devices designed to treat abdominal
aortic aneurysms (AAA) have been developed. Evaluating
the safety and efficacy of these devices continues in random-
ized trials2,3 and nonrandomized trials.4-8 In 1997, a fea-
sibility study was undertaken to evaluate the safety, the
accuracy of placement, and the reliability of deployment of
the original EXCLUDER Bifurcated Endoprosthesis (WL
Gore & Associates; Flagstaff, Ariz) for the treatment of
AAA. The results of this investigation have previously been
reported elsewhere.9 This original investigation was fol-
lowed a year later by a pivotal nonrandomized controlled
clinical trial with the objectives to evaluate the safety of
EVAR compared with open surgical repair and the effec-
tiveness of EVAR to exclude the AAA from the blood
circulation with the intent to prevent aneurysm related
death. Two-year interim results have been published,10 and
this study presents the 5-year long-term outcomes.
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The trial design has been previously published in de-
tail.10 Briefly, enrollment in this multicenter, concurrent-
controlled trial occurred from December 1998 to January
2000, at 19 institutions across the United States. Institu-
tional review board approval was obtained at each site.
Devices were deployed in accordance with the labeled
instructions for use.
Follow-up. Patients were seen in follow-up at 1, 6,
and 12 months postprocedure, and yearly thereafter. Both
test and control subjects were followed for 5 years. Impor-
tantly, subjects were not discharged from the study rou-
tinely after conversion or explantation. At the time of the
follow-up visits, patients received a physical examination,
endovascular protocol CT scan, and four-view plain radio-
graphs (in test subjects only). Each institution’s principle
investigator was responsible for submission of clinical data,
and a core laboratory reviewed all radiographic studies
independently. Corelab interpretation is being reported
because it has uniform methodology across sites. Clinical
evaluations are included regardless of whether corelab data
is available for a visit interval. The device-specific radio-
graphic characteristics that were evaluated by the corelab
included evidence of limb narrowing, trunk, contralateral
leg, aortic extender, and iliac extender component migra-
tion, stent fracture, endoleak, and aneurysm size change.
Trunk or extender migration was considered significant if it
was associated with another complication (ie, endoleak or
major adverse event), or moved by10mm from the initial
postoperative imaging modalities. Aneurysm size change
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ameter at each follow-up visit to the baseline. The baseline
measurement was taken from the first postoperative imag-
ing. Aneurysm growth by5mm compared to the baseline
measurement was considered significant.
Prior to final data cut-off, there were 128 eligible test
patients entering the 5-year interval. Of these 128 test
patients, 14 withdrew from the study in the final year, and
3 missed the follow-up visit in the 5-year window. This left
111 test patients available for follow-up in the 5-year win-
dow. Of these 111 test patients, 102 had CT scans. Corelab
was unable to assess for specific radiographic parameters
such as endoleak or migration when there were limitations
of imaging (ie, no pre- and postcontrast imaging may
compromise the ability to assess for endoleak or lack of
paired thin slice reconstructions may preclude accurate
assessment of migration). This results in a slightly different
denominator of assessable subjects for each corelab param-
eter.
Adverse events. Adverse events were defined in accor-
dance with the definitions previously published by Sacks et
al11 and are categorized as follows: major adverse events
(MAE)- (1) requires therapy and short hospitalization (24
to 48 hours), (2) requires major therapy, unplanned in-
crease in level of care, or prolonged hospitalization (48
hours), (3) requires permanent adverse sequelae, or (4)
requires death. Furthermore, specifically included as MAE
are any reinterventions (including conversions) after EVAR
and any complications of reinterventions. Aneurysm-
related death was defined as death during the same hospi-
talization or within 30 days of the initial procedure or any
reintervention, or death related to the aneurysm or device.
By this definition, aneurysm-related mortality includes
deaths that are the result of complications after conversion
to an open procedure.
Statistical analysis. The final cut-off for the collection
of the 5-year data including clinical evaluations and corelab
radiographic results occurred on August 7, 2006. Results
are reported as mean standard deviation where appropri-
ate; log-rank tests are used to compare overall survival,
aneurysm-related survival, and freedom from any MAE
throughout follow-up. P values .05 were considered sta-
tistically significant. The time-related accumulation of ma-
jor adverse events within each treatment group was esti-
mated by the Nelson nonparametric method.12 The mean
cumulative function (MCF) is a nonparametric estimate of
the mean number of major adverse events experienced by
subjects over time. Similar to the Kaplan-Meier estimates,
the MCF estimation accounts for censoring (including
drop out and lost-to-follow-up) of subjects. Graphically,
this population mean curve is a step function with many
small steps, one for each event in the population. The plots
shown in Fig 1 and Fig 2 were created using the Reliability
Procedure in the SAS/QC software of SAS Institute (SAS
Institute, Inc., Cary, NC). There is no omnibus statistical
test for comparing MCF curves, and exploratory 95% con-
fidence limits are plotted at 1 month, 6 months, and annual
intervals.RESULTS
Patient demographics. Three hundred thirty-four
patients were included in this study and underwent either
standard open repair of AAA (n  99; control group) or
EVAR (n  235; test group). Baseline demographics,
physical characteristics, laboratory values, and anatomic
variables have been previously detailed,10 and there were
few significant differences, including: test group had a
higher percentage of male subjects, had mean age that was
3 years greater, had higher mean blood urea nitrogen and
serum creatinine levels, and had a higher percentage of
subjects with hyperlipidemia.
Overall survival. As shown in Fig 3, survival is com-
parable between test and control subjects (at 60 months,
the survival rates are 72% test vs 81% control). Over the 60-
month follow-up period, the survival difference is not sta-
tistically significant (P  .12; log rank test).
Review of the primary causes of death throughout the
5-year follow-up period demonstrates that both groups
experienced a similar pattern. Subjects died of cardiac,
neoplastic, pulmonary, and neurologic causes in decreasing
order of frequency in both groups. There were no deaths
due to aneurysm rupture.
Aneurysm-related survival. Freedom from aneurysm-
related mortality is shown in Fig 4. Rates for test and
control are similar, with four aneurysm-related deaths in
the test group and two aneurysm-related deaths in the
control group during the first 12 months. Between the
12- and 60-month follow-up, there were two additional
aneurysm-related deaths in the test group and no additional
aneurysm-related deaths in the control group (at 60
Fig 1. Curves show the time-related accumulation of major ad-
verse events (MAE) within the control (dashed) and test (solid)
groups estimated by the Nelson nonparametric method. Through
the 60-month follow-up period, the total mean cumulative MAE
for control subjects was 3.2 events/subject compared with test
subjects with 2.4 events/subject.months, the survival rates are 97% test vs 98% control). One
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uted to aspiration pneumonia, which occurred after open
surgical explantation of an infected endoprosthesis. The
other death was due to prosthetic valve endocarditis after a
surgical conversion for aneurysm expansion. Over the 60-
month follow-up period, the aneurysm-related survival dif-
ference is not statistically different (P  .8; log rank test).
Major adverse events. In contrast to the similarities
seen between the two groups in terms of overall and
aneurysm-related survival at 5-year follow-up, there is a
significant difference in the freedom from MAE seen be-
tween the two groups. Fig 5 displays the time-related
Fig 2. Mean cumulative function (MCF) difference in major
adverse events (MAE) between test and control groups. Error bars
represent 95% confidence limits.
Fig 3. Kaplan-Meier curves show overall survival in both control
(dashed) and test (solid) groups. Over the 60-month follow-up
period, the survival difference is not statistically significant (P 
.12). Also shown is the number of patients at risk in each popula-
tion at annual increments over 5 years.proportion of subjects that remained free of a major adverseevent. At 12 months, test subjects had a higher proportion
that remained free of a major adverse event compared with
controls (65% test vs 26% control). This safety advantage
for the test group is maintained between 12- and 60-month
follow-up (at 60 months, the proportion free from MAE
are 31% test vs 15% control). Over the 60-month follow-up
Fig 4. Curves show percentage of patients in control (dashed)
and test (solid) groups free from aneurysm-related mortality. Over
the 60-month follow-up period, the aneurysm-related survival
difference is not statistically different (P  .8). Also shown is the
number of patients at risk in each population at annual increments
over 5 years.
Fig 5. Curves show percentage of patients in control (dashed)
and test (solid) groups free from major adverse events (MAE).
Over the 60-month follow-up period, the freedom from MAE is
significantly greater for the test group compared with the control
group (P  .001). Also shown is the number of patients at risk in
each population at annual increments over 5 years.period, the freedom from major adverse events is signifi-
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 .001; log rank test) and strongly support that EVARwith
the test device is safer compared to standard open surgery
over the 60-month follow-up period.
Included in the calculation of MAE for the test group
were reinterventions such as conversion to open surgery
and resultant complications. Of the 235 patients in the test
group, there were 57 reinterventions, including 33 (58%)
embolization procedures and 10 surgical conversions. The
Table shows the incidence of reinterventions, which are
more frequent in the first 2 years after implantation. In one
patient who had undergone several previous angiograms
and coil embolization procedures, there was evidence of an
aorto-enteric fistula seen at the 49-month follow-up lead-
ing to open conversion for infected endoprosthesis (previ-
ously described). There were two conversions (at 28 and 52
months postprocedure) secondary to aneurysm sac enlarge-
ment associated with endoleak. Seven patients underwent
conversion to open procedure (range 24 to 62 months
postprocedure) for aneurysm sac enlargement without ev-
idence of endoleak.
In the 5-year corelab evaluation of patients undergoing
EVAR there is 0% limb narrowing (0/77), 0% stent fracture
(0/74), 0% component (contralateral leg, aortic extender,
or iliac extender) migration (0/75), 0% trunk migration
(0/70), and 3% endoleak (2 type II/68). No patient had
migration, type I or type III endoleak reported by corelab
or sites at 5 years in this study, but with larger datasets, rare
events are likely to be identified. After 5 years, 32 patients
(41%) were noted to have stable aneurysms in terms of size,
16 patients (21%) were noted to have a decrease in aneu-
rysm size, and 30 patients (38%) were noted to experience
aneurysm sac enlargement.
Of the 30 patients with sac enlargement at 60 months,
three patients were noted previously to have had type II
endoleaks at some point during follow-up, two had en-
doleaks of indeterminate source, 22 patients had no en-
doleak, and three were not assessed by corelab for en-
doleak. These 30 patients have had 11 reinterventions: 10
coil embolizations and one ligation of the inferior mesen-
teric artery. The mean aneurysm diameter of these 30
patients is 6.8cm at 5 years. None of these patients have
developed device or component migration, or clinical se-
quelae of hemorrhagic or nonhemorrhagic rupture.
Cumulative adverse effects. As many subjects suffer
more than one MAE, analysis of cumulative MAE is en-
lightening. Fig 1 displays characteristics of cumulative ma-
Table. Reinterventions table for test subjects listing the nu
along with the number of reinterventions and number of s
Report Detailed and/or
summarized report 6 Months 12 Months
Subjects available for evaluation 230 221
Subjects with any reintervention 10 (4.3%) 8 (3.6%)
Total number of reinterventions 10 8jor adverse events over the 60-month follow-up for test andcontrol groups. The control group accumulates major ad-
verse events more quickly during the first month. After the
first month, the two treatment groups maintain a similar
pattern in the mean cumulative major adverse event rates,
with the mean consistently higher for the control group
over the 60-month follow-up period. Through 1 year, the
total mean cumulative events for test subjects was 0.8
events/subject compared with controls with 1.9 events/
subject. Through 60 months, the total mean cumulative
events for test subjects was 2.4 events/subject compared
with controls with 3.2 events/subject.
The MCF difference of MAE between test and control
groups is depicted in Fig 2. The graph illustrates the
persistent difference in cumulative MAE between the two
groups. Ninety-five percent confidence limits widen over
time as the sample size decreases. The MCF difference
curve permits assessment of the impact of later complica-
tions and reinterventions over 5 years compared with the
initial differences between test and control groups.
DISCUSSION
Numerous endovascular devices have been evaluated
for treatment of abdominal aortic aneurysms, and each
possesses unique characteristics. EVAR with most of these
devices has shown improved short-term results in periop-
erative morbidity and mortality when compared with open
surgical repair, but there are concerns about whether these
benefits will persist in the long term because of the higher
reintervention rates with EVAR. In the previously pub-
lished report, striking short-term advantages of EVAR over
open surgical repair of AAA was apparent.10 This study
demonstrated decreased blood loss, fewer homologous
transfusions, and shorter length of stay in comparison to
the control group. Early MAE were markedly reduced in
the test group (14% vs 57%), and this difference persisted at
2-year follow-up. There was no difference in survival be-
tween the two groups at 2 years. A concern was that
reinterventions may result in loss of these early benefits of
EVAR. The current study follows these same patients out
to 5 years postprocedure and demonstrates persistent ben-
efit of reduced MAE with EVAR compared with standard
open repair of AAA. It also demonstrates a similar overall
survival and aneurysm-related survival, although the study
was not powered to evaluate survival differences.
Other limitations of this study include the nonrandom-
ized design and relatively small sample size of patients who
had 5-year corelab imaging follow up. The nonrandomized
r of subjects available for evaluation at each time point
ts undergoing reinterventions at each time point
24 Months 36 Months 48 Months 60 Months
213 185 161 128
16 (7.5%) 3 (1.6%) 7 (4.3%) 3 (2.3%)
17 3 8 3mbe
ubjecdesign of the trial may have led to a different risk profile as
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ously reported, including mean age 3 years greater, higher
mean blood urea nitrogen, higher mean serum creatinine,
and anatomic differences necessary for EVAR in the test
cohort compared with control group.10 During the course
of 5 years, many subjects withdrew from the study, died, or
were otherwise lost to follow-up. The smaller sample size of
subjects with corelab data did not identify any aneurysm
rupture, type I or III endoleak, fracture, or migration; and
larger datasets such as in postapproval studies are being
gathered to determine the incidence of these rare events.
After 5 years follow-up, there were ten conversions to
open procedures in the test group (4.3% of the original test
cohort). The reasons for conversion are interesting. In-
cluded in these conversions were two patients with en-
doleaks and aneurysm sac enlargement seen at 28 and 52
months postprocedure. There were seven additional pa-
tients who underwent open conversion between 24 and 62
months post-EVAR for aneurysm sac enlargement without
demonstrable endoleak. The final conversion was in a pa-
tient who had undergone selective catheterization of the
superior mesenteric artery and inferior mesenteric artery
(IMA) collaterals with embolization who was noted to have
persistent endoleak 1 year later necessitating another em-
bolization for progressive enlargement of the aneurysm. At
36-month follow-up, this patient was noted to have devel-
oped another type II endoleak of unknown origin and had
growth in the aneurysm, and this was followed. At 48-
month follow-up, the endoleak had resolved and the aneu-
rysm sac was smaller, but on imaging air was noted in the
aneurysm sac indicating possible stent-graft infection.
Therefore, this patient underwent open surgical conversion
with graft removal and died after complications following
the open conversion. This series of conversions from 24 to
62 months postprocedure emphasizes the need for contin-
ued surveillance beyond 2 years and opportunities for de-
vice improvements.
Not only is continued surveillance important for deter-
mining the need for open conversion, but it is also impor-
tant in determining if reintervention using endovascular
techniques is needed. Significant aneurysm growth, defined
as diameter increase of 5 mm compared to baseline, was
seen in 38% of patients in the test group at 5 years. Of note,
there were no aneurysm ruptures in this group, but 11
reinterventions were done in these subjects throughout the
5-year follow-up period. Ten of these reinterventions in-
cluded coil embolization procedures, and there was one
patient who underwent ligation of the IMA. Including
these reinterventions as MAE, the test group still experi-
enced an advantage of freedom from any MAE in compar-
ison to the control group.
Despite aneurysm sac enlargement in almost two-fifths
of the test population, it is noteworthy that there were no
aneurysm ruptures. While there has been concern that
morphology changes of the aneurysm neck with sac growth
may adversely affect the stability and adequacy of the stent-
graft in excluding the aneurysm from the native circulation,
this was not evident at 5-year follow-up after EVAR. Otherreports concur that neck fixation is stable with endotension
with three different endograft devices.13 No new type I
endoleaks were seen in a detailed analysis of neck apposition
by 3-D CT reconstruction in patients treated with this
device with midterm sac growth by site or corelab interpre-
tation, including a patient with an initially poor neck and a
patient with decreasing apposition distance.14 In a detailed
study of a cohort of conversions from five different trials of
similar devices, one patient had an initial type I endoleak
related to severe 90 degree neck angulation and another
patient who developed a paravisceral aneurysm had the
endograft removed during the open thoracoabdominal re-
pair.15 There were no other type I endoleak or fixation
concerns. Taken together, these studies and the corelab
data reported here suggest that late type I endoleak rarely,
if ever, results from sac growth. Nonetheless, it is prudent
to follow neck apposition length as it may shorten and
potentially lead to loss of seal.
It is interesting that 22 of the 30 patients who experi-
enced aneurysm sac enlargement had no demonstrable
endoleak throughout the 60-month follow-up. This was
initially a perplexing issue for the treating physician and has
been addressed with continued observation, laparoscopic
or open aneurysm sac decompression, endograft relining,
and open conversion.16-18 While intervention is technically
possible, we caution that it may not be necessary in most
instances, as the clinical significance of aneurysm sac en-
largement without endoleak could be non-hemorrhagic
rupture.13,19 Conversion to open procedure in patients
with aneurysm enlargement after EVAR has been shown to
be a hazardous procedure.20 While most treating physicians
believe that patients experiencing aneurysm enlargement in
the setting of persistent endoleak may be candidates for
reintervention, the need for these secondary procedures in
patients without endoleak is unclear. No concrete scientific
evidence exists to guide management of these patients.
Clearly, almost all ruptures following EVAR have occurred
in the setting of known or acute endoleak.21,22 These data
show that the 30 aneurysms that expand without evidence
of endoleak did not rupture over 5 years.
Various mechanisms have been speculated for aneu-
rysm sac enlargement without endoleak and include
inability to detect the presence of small endoleaks using
conventional imaging modalities, inadequate seal zones
that results in thrombus being in contact with the native
circulation, and ultrafiltration through the graft materi-
al.14,17,18,23-28 However, based on explant analysis, in-
formation gathered from surgical conversion proce-
dures, and in vitro animal studies,15,29,30 the movement
of serum and fibrin components through the ePTFE
graft material used in this device is the predominant
contributing factor to the fluid accumulation. It is not
clear why this phenomenon occurs in only a minority of
patients. The graft composition has been modified to
stop ultrafiltration, and another multicenter trial will
assess the clinical result of eliminating transmural move-
ment of serous fluid through the device and aneurysm sac
growth. A preliminary two-center study suggests that at
JOURNAL OF VASCULAR SURGERY
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rate of aneurysm dilatation.31
SUMMARY
Five year results of this controlled trial demonstrate
that EVAR has fewer major adverse events compared with
open repair. Overall and aneurysm-related survival between
the two groups is not different. Aneurysm sac growth due
to transgraft ultrafiltration occurs frequently with the orig-
inal device design and has been addressed with subsequent
graft modification.
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